4D Molecular Therapeutics, Inc. (FDMT) vs Fulgent Genetics, Inc. (FLGT)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Fulgent Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.93HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
FLGT
Fulgent Genetics, Inc.
$20.83HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — FDMT vs FLGT
growth of $100 · dividends reinvested · last 6yFDMT -68.1% (-17.3%/yr)FLGT -53.2% (-11.9%/yr)FLGT compounded faster over this window
FDMT FLGT
FDMT vs FLGT: by the numbers
- •FDMT is the larger company ($676M vs $592M market cap).
- •Both run net losses; FLGT's is the smaller (-26.05% vs -194.74% net margin).
- •FDMT grew revenue faster over the past five years (31.93% vs -18.66% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | FLGT |
|---|---|---|
| P/S ratio | 7.35 | 1.83 |
| P/B ratio | 1.66 | 0.59 |
Profitability
| Metric | FDMT | FLGT |
|---|---|---|
| Gross margin | 91.05% | 35.58% |
| Operating margin | -187.24% | -28.23% |
| Net margin | -194.74% | -26.05% |
| ROE | -43.95% | -8.42% |
| ROIC | -44.30% | -11.80% |
Growth (annualized)
| Metric | FDMT | FLGT |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | -18.66% |
| Total return CAGR (5Y) | -13.08% | -22.38% |
Frequently asked
- Which has grown faster, FDMT or FLGT?
- Over the past five years, FDMT grew revenue faster — FDMT at a 31.93% CAGR versus FLGT at -18.66%.
- How have FDMT and FLGT total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and FLGT delivered -22.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROEFulgent Genetics ROE4D Molecular Therapeutics operating marginFulgent Genetics operating margin4D Molecular Therapeutics revenue growthFulgent Genetics revenue growth4D Molecular Therapeutics free cash flowFulgent Genetics free cash flow
4D Molecular Therapeutics & Fulgent Genetics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.